As Alnylam approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra to treat patients in an increasingly competitive indication—transthyretin amyloid cardiomyopathy (ATTR-CM)—the company is emphasizing the growth of the market. More: Alnylam touts Amvuttra's
read moreThe geographic atrophy drug can now be dosed beyond a 12-month window, a prior label restriction that led many patients to pause treatment. More: Astellas' eye med Izervay lands key FDA label update, amping up market battle with Apellis rival
read moreThe Senate on Thursday voted 52-48 to confirm President Donald Trump’s nominee for health secretary. More: It’s official: Senate votes to confirm RFK Jr. as HHS secretary Source: fierce
read moreSpanish drugmaker Rovi warned this month that analyst consensus estimates for its annual profits in 2024 are likely 10% to 15% too high. The CDMO said its slimmed-down profit outlook is “due basically to lower expected activity in the contract
read moreTelehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its weight loss program, which offers access to compounded semaglutide. Now, semaglutide maker Novo Nordisk is chiming in. More: 'We cannot
read moreMore than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green light to treat large B-cell lymphoma. More: Pfizer's blockbuster ADC Adcetris nabs FDA approval to treat large B-cell lymphoma Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals